While companies in the opiod sector have had to deal with headlines about abuse as well as pharma pricing controversies, Depomed reported increased sales across its product line.
Starboard CEO Jeff Smith and two others are joining the board. The activist investor will also recommend two additional directors.
TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.
The Dow Jones Industrial Average's march to 20,000 hit another roadblock on the first trading day of the year as crude oil prices reversed course.